First Author: M.Gil Martinez SPAIN
Co Author(s): M. Rodriguez Cid M. Fernandez Rodriguez M. Abraldez Lopez Veiga F. Gomez-Ulla de Irazazabal
Back to previous
To evaluate the efficacy of intravitreal aflibercept for treatment of diabetic macular edema (DME) in Real-Life Clinical Practice
Department of Ophthalmology, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.
In this retrospective study, 18 DME patients were treated with intravitreal aflibercept with 12 months of follow-up. In our serie we have two groups: Naïve patients (group 1, n=6) and patients with DME previously treated with ranibizumab (Group 2, n=12). We have analysed improvement in best corrected visual acuity and decreased central foveal thickness using optical coherence tomography at 6 and 12 months in both groups.
Best-corrected visual acuity increased by a mean of 10,47 letters at Month 6 and 8,82 at month 12 in naive patients. Whereas in switching patients best-corrected visual acuity increased by a mean of 10,47 at month 6 and 8,59 at month 12. The proportion of eyes achieving at least a 15-letter improvement from baseline was 38.8% at Month 12. Moreover, the proportion of eyes achieving at least a 10-letter improvement from baseline was 44,4% at month 12. Central macular thickness decreased from 627,12μm to 313 μm at month 6 and 333,06μm at month 12 in Group 1. In Group 2, central macular thickness decreased from 643,82μm to 321,94μm at month 6 and 325,82 at month 12.
This case series study showed favourable at one year outcomes when using aflibercept to treat DME. Aflibercept provides long-term visual and functional benefits in the treatment of DME in real-life .